###### Strengths and limitations of this study

-   This is the ﬁrst original study on the association between splenectomy and empyema.

-   We used a hospitalisation dataset with a large sample size and great statistical power.

-   Some traditional behaviour risk factors including alcohol consumption and cigarette smoking were not recorded due to the inherent limitation of this insurance database.

-   This case--control study included only patients with splenectomy, which may limit the generalisability of the study results to the general population.

-   Such a study design does not permit to conclude a substantial causality.

Introduction {#s1}
============

Pleural empyema is a suppurative infection of the pleural cavity. The aetiology of empyema is classified as two distinct mechanisms. Empyema most commonly occurs following pneumonia as microorganisms spread directly into the pleural cavity. This occurs in approximately 1%--5% of pneumonia cases.[@R1] The second mechanism occurs following surgery, most commonly of the thorax, oesophagus, lung or heart. Although empyema is an ancient disease with centuries of learnt experience, it continues to be an important clinical problem. Despite the use of antibiotics and different pneumococcal vaccines, empyema remains the most common complication of pneumonia and is an important cause of morbidity worldwide.[@R3] The development of antibiotics in the first half of the 20th century significantly contributed in decreasing the incidence of pleural infection. However, this trend shifted at the end of the 20th century, and the incidence of empyema has tended to increase worldwide.

The human spleen mainly serves as an immune responder against invading microorganisms.[@R4] Immunological responses and haematological functions of the human spleen are well known. The spleen, mediated by the innate and adaptive immunity, protects the body against infections.[@R6] Therefore, patients with splenectomy are more likely than those without splenectomy to develop severe life-threatening infections. Splenectomy is associated with an increased risk of some diseases, including pulmonary tuberculosis, type 2 diabetes mellitus, pyogenic liver abscess, renal and perinephric abscesses, and acute pancreatitis[@R8]; however, to our knowledge, postsplenectomy empyema has not yet been studied.

Despite the trend of increasing incidence of empyema worldwide, no study has evaluated the association between splenectomy and empyema. Here we rationally hypothesise an association between splenectomy and empyema owing to the immunocompromised condition induced by splenectomy, which can further increase the risk of microorganism invasion of the pleural cavity. However, there is limited published literature regarding epidemiological studies on this issue. As splenectomy is associated with overwhelming postsplenectomy infections and empyema carries potential fatality, exploring the risk of empyema in patients with splenectomy may have signiﬁcant clinical and public health implications. Therefore, to explore whether an association between splenectomy and empyema exists, we conducted a nationwide cohort study using the hospitalisation dataset of the Taiwan National Health Insurance Program.

Methods {#s2}
=======

Study design and data source {#s2a}
----------------------------

Taiwan is an independent country with over 23 million people.[@R13] We conducted a population-based cohort study using insurance claim data from the Taiwan National Health Insurance Program, which has covered 99% of the Taiwan population since 1995 and thus is a thorough representative sample of the population.[@R18] The details of the insurance program have been well documented in previous studies.[@R19] This study was approved by the Research Ethics Committee of China Medical University and Hospital in Taiwan (CMUH-104-REC2-115).

Study subjects {#s2b}
--------------

Using the hospitalisation dataset of the Taiwan National Health Insurance Program, all hospitalised subjects aged 20--84 years who underwent splenectomy (International Classification of Diseases, Ninth Revision, Clinical Modification, ICD-9 procedure code 41.5) between 1 January 2000 and 31 December 2010 were categorised in the splenectomy group. The year of undergoing splenectomy was defined as the index year. For each subject in the splenectomy group, four subjects who did not undergo splenectomy were randomly selected from the same database and were categorised in the non-splenectomy group. Both groups were matched with regard to sex, age (every 5-year span), comorbidities and the index year of undergoing splenectomy. To reduce potentially biased results, subjects with an empyema diagnosis (ICD-9 codes 510, 511.1, 511.8 and 511.9) within 1 month following splenectomy were excluded.

Outcome and comorbidities {#s2c}
-------------------------

The main outcome was a new diagnosis of empyema on the basis of hospital discharge registries during the follow-up period. Each subject was monitored from the index year until being diagnosed with empyema; being censored because of the loss to follow-up, death or withdrawal from insurance; or at the end of 31 December 2011, namely the end of the study. The following comorbidities were investigated: alcohol-related disease, cancer, chronic kidney disease, chronic liver disease (including cirrhosis, alcoholic liver damage, hepatitis B, hepatitis C and other chronic hepatitis), chronic obstructive pulmonary disease and diabetes mellitus. All comorbidities were diagnosed according to the ICD-9 codes, which have been well assessed in previous studies.[@R23]

Statistical analysis {#s2d}
--------------------

The differences between the splenectomy and non-splenectomy groups with respect to sex, age and comorbidities were compared using the χ^2^ test for categorical variables and t-test for continuous variables. The subject's sex, age and follow-up period (in person-years) were used to estimate incidence rate and incidence rate ratio (IRR) of the splenectomy group to the non-splenectomy group with 95% CI using Poisson regression. Multivariable Cox proportional hazards regression model was used to estimate the HR with 95% CI of empyema associated with splenectomy and other comorbidities, after simultaneously adjusting for confounding variables in the univariable Cox proportional hazard regression model. The proportional hazard model assumption was examined using a test of scaled Schoenfeld residuals. The results of the model that evaluated the risk of empyema throughout the follow-up period revealed a significant association between Schoenfeld residuals for splenectomy and follow-up period, suggesting that the proportionality assumption was violated (p\<0.001). In the subsequent analysis, we stratified the follow-up period to avoid violation of the proportional hazard assumption. All statistical analyses were performed using SAS V9.2 (SAS Institute, Cary, North Carolina, USA). Two-tailed p values of\<0.05 were considered to be statistically significant.

Results {#s3}
=======

Baseline data of the study subjects {#s3a}
-----------------------------------

[Table 1](#T1){ref-type="table"} shows the baseline data of the study subjects. A total of 13 193 subjects with splenectomy and 52 464 subjects without splenectomy were included, with similar distributions in sex and age. Mean ages (mean±SD) were 52.8±17.2 years in the splenectomy group and 52.5±17.2 years in the non-splenectomy group (t-test; p=0.05). Mean follow-up periods (mean±SD) were 4.37±3.44 person-years in the splenectomy group and 5.75±3.32 person-years in the non-splenectomy group (t-test; p\<0.001). There was no significant difference in the prevalence of comorbidities between the splenectomy and non-splenectomy groups (χ^2^ test; p\>0.05 for all).

###### 

Baseline characteristics between splenectomy group and non-splenectomy group

  Variable                                 Splenectomy   p Value\*                   
  ---------------------------------------- ------------- ----------- ------ -------- ---------
  Sex                                                                                0.88
   Female                                  20 431        38.9        5128   38.9     
   Male                                    32 033        61.1        8065   61.1     
  Age group (years)                                                                  0.98
   20--39                                  13 415        25.6        3364   25.5     
   40--64                                  24 112        46.0        6062   46.0     
   65--84                                  14 937        28.5        3767   28.6     
   Age (years), mean (SD)†                 52.5          (17.2)      52.8   (17.2)   0.05
   Follow-up period (years), mean (SD)†    5.75          (3.32)      4.37   (3.44)   \<0.001
  Baseline comorbidities                                                             
   Alcohol-related disease                 1787          3.41        452    3.43     0.91
   Cancer                                  7677          14.6        1962   14.9     0.49
   Chronic kidney disease                  1068          2.04        270    2.05     0.94
   Chronic liver disease                   7791          14.9        1971   14.9     0.80
   Chronic obstructive pulmonary disease   2002          3.82        507    3.84     0.89
   Diabetes mellitus                       7856          15.0        1983   15.0     0.87

Data are presented as the number of subjects in each group, with percentages given in parentheses, or mean with SD given in parentheses.

\*χ^2^ test, and

†*t*-test comparing subjects with and without splenectomy.

Incidence of empyema stratified by sex, age and follow-up period {#s3b}
----------------------------------------------------------------

[Table 2](#T2){ref-type="table"} shows the incidence rates of empyema. At the end of the cohort study, the overall incidence rate of empyema was 2.56-fold higher in the splenectomy group than in the non-splenectomy group (8.85 vs 3.46 per 1000 person-years; 95% CI 2.44 to 2.69). The incidence rate of empyema, stratified by sex, age and follow-up period, was higher in the splenectomy group than in the non-splenectomy group. The incidence rate of empyema increased with age in both the groups, with the highest rate reported in the splenectomy group with subjects aged 65--84 years (19.2 per 1000 person-years). Stratified analysis by follow-up period revealed that the incidence rate of empyema decreased with the follow-up period in both the groups. The risk of empyema in the splenectomy group was significantly higher in the first 5 years of follow-up (IRR, 2.87; 95% CI 2.73 to 3.01). However, risk of empyema continued to exist in the splenectomy group even after 5 years (IRR, 1.73; 95% CI 1.60 to 1.88).

###### 

Incidence density of empyema estimated by sex, age and follow-up period between splenectomy group and non-splenectomy group

  Variable                   Non-splenectomy   Splenectomy   IRR†       (95% CI)                                         
  -------------------------- ----------------- ------------- ---------- ---------- -------- ----- -------- ------ ------ ----------------
  All                        52 464            1042          3 01 484   3.46       13 193   510   57 622   8.85   2.56   (2.44 to 2.69)
  Sex                                                                                                                    
   Female                    20 431            317           1 19 441   2.65       5128     159   23 004   6.91   2.60   (2.40 to 2.82)
   Male                      32 033            725           1 82 042   3.98       8065     351   34 618   10.1   2.55   (2.39 to 2.71)
  Age group (years)                                                                                                      
   20--39                    13 415            57            84 004     0.68       3364     65    19 700   3.30   4.86   (4.39 to 5.39)
   40--64                    24 112            354           1 40 554   2.52       6062     224   26 423   8.48   3.37   (3.13 to 3.62)
   65--84                    14 937            631           76 925     8.20       3767     221   11 499   19.2   2.34   (2.14 to 2.56)
  Follow-up period (years)                                                                                               
   \<5                       52 464            720           2 06 010   3.49       13 193   416   41 545   10.0   2.87   (2.73 to 3.01)
   ≥5                        28 456            322           95 474     3.37       5052     94    16 077   5.85   1.73   (1.60 to 1.88)

\*Incidence rate: per 1000 person-years.

†IRR (incidence rate ratio): splenectomy versus non-splenectomy (95% CI).

The Kaplan-Meier model revealed a higher cumulative incidence of pleural empyema in the splenectomy group than in the non-splenectomy group (6.99% vs 3.37% at the end of follow-up; p\<0.001; [figure 1](#F1){ref-type="fig"}).

![Kaplan-Meier model revealed that the splenectomy group had a higher cumulative incidence of pleural empyema than the non-splenectomy group (6.99% vs 3.37% at the end of follow-up; p\<0.001).](bmjopen-2016-015101f01){#F1}

HR of empyema associated with splenectomy and other comorbidities {#s3c}
-----------------------------------------------------------------

[Table 3](#T3){ref-type="table"} displays HR of empyema associated with splenectomy and other comorbidities. Variables that were found to be statistically significant in the univariable model were further examined in the multivariable model. After adjusting for age, sex, alcohol-related disease, cancers, chronic kidney disease, chronic liver disease, chronic obstructive pulmonary disease and diabetes mellitus, the multivariable Cox proportional hazards regression model revealed that the adjusted HR of empyema was 2.89 in the splenectomy group (95% CI 2.60 to 3.22) compared with that in the non-splenectomy group.

###### 

Adjusted HR and 95% CI of empyema associated with splenectomy and other comorbidities

  Variable                                 Crude   Adjusted\*              
  ---------------------------------------- ------- ---------------- ------ ----------------
  Sex (male vs female)                     1.48    (1.33 to 1.65)   1.51   (1.35 to 1.68)
  Age (per 1 year)                         1.05    (1.04 to 1.05)   1.05   (1.05 to 1.06)
  Baseline comorbidities (yes vs no)                                       
   Splenectomy                             2.52    (2.26 to 2.80)   2.89   (2.60 to 3.22)
   Alcohol-related disease                 1.61    (1.28 to 2.03)   2.25   (1.76 to 2.86)
   Cancer                                  2.60    (2.31 to 2.92)   1.92   (1.71 to 2.17)
   Chronic kidney disease                  3.04    (2.40 to 3.85)   2.13   (1.67 to 2.70)
   Chronic liver disease                   2.07    (1.84 to 2.34)   1.90   (1.68 to 2.14)
   Chronic obstructive pulmonary disease   3.95    (3.37 to 4.64)   1.75   (1.48 to 2.07)
   Diabetes mellitus                       2.80    (2.51 to 3.13)   1.85   (1.65 to 2.07)

Adjusted for age, sex, alcohol-related disease, cancer, chronic kidney disease, chronic liver disease, chronic obstructive pulmonary disease and diabetes mellitus.

\*Variables found to be statistically significant in the univariable model were further examined in the multivariable model.

Interaction effect between splenectomy and other comorbidities on the risk of empyema {#s3d}
-------------------------------------------------------------------------------------

[Table 4](#T4){ref-type="table"} displays the interaction effect between splenectomy and other comorbidities, including alcohol-related diseases, cancers, chronic kidney disease, chronic liver diseases, chronic obstructive pulmonary diseases and diabetes mellitus, on the risk of empyema. The adjusted HR of empyema was 4.52 for subjects with splenectomy alone and without any comorbidity (95% CI 3.80 to 5.37). HR markedly increased to 8.23 for subjects with splenectomy and with any comorbidity (95% CI 6.98 to 9.70), demonstrating an interaction effect between splenectomy and other comorbidities on the risk of empyema.

###### 

Cox proportional hazard regression analysis for risk of empyema stratified by splenectomy and comorbidities

  Variable   Event   Incidence\*   Adjusted HR† (95% CI)   
  ---------- ------- ------------- ----------------------- ---------------------
  No         No      299           1.49                    1 (Reference)
  No         Yes     743           7.34                    3.64 (3.18 to 4.17)
  Yes        No      230           5.75                    4.52 (3.80 to 5.37)
  Yes        Yes     280           15.9                    8.23 (6.98 to 9.70)

\*Incidence rate: per 1000 person-years.

†Adjusted for sex and age.

‡Comorbidities including alcohol-related disease, cancer, chronic kidney disease, chronic liver disease, chronic obstructive pulmonary disease and diabetes mellitus.

Discussion {#s4}
==========

Sinwar[@R34] found that the duration between splenectomy and the onset of overwhelming postsplenectomy infections could range from \<1 week to \>20 years. To reduce biased results, patients who underwent splenectomy within 1 month of empyema diagnosis were excluded to ensure that splenectomy truly preceded the onset of empyema.

Extensive evidence has supported the protective role of the human spleen against invading microorganisms on the basis of the bactericidal capacity of lymphoid cells and macrophages, as well as humoral immune response.[@R6] Following splenectomy, normal immune functions such as phagocytic activity and humoral immune response may be signiﬁcantly changed. Therefore, impaired postsplenectomy immune functions may increase the risk of a life-threatening infection and empyema. In our study, the risk of empyema in the splenectomy group was higher in the first 5 years of follow-up than after the first 5 years (IRR, 2.87 vs 1.73). However, the risk of empyema continued to exist in the splenectomy group, even after the first 5 years. These ﬁndings are compatible with previously reported findings that revealed that the majority of severe infections occur within the ﬁrst 3 years following splenectomy; although the risk declines over time, it may last for \>5 years following splenectomy.[@R38] However, the exact mechanism underlying this risk remains unknown. We speculate that with time, the immune system may develop compensatory mechanisms that may overcome these immune deficits. Future studies are required to confirm this hypothesis.

To the best of our knowledge, this population-based cohort study is the first to reveal that splenectomy is associated with an increased HR of empyema (adjusted HR, 2.89). Some studies have reported that splenectomy is associated with an increased risk of diseases. Lai *et al* compared between splenectomy patients and non-splenectomy patients and found that for postsplenectomy patients, the adjusted OR of acute pancreatitis was 2.90 (95% CI 1.39 to 6.05),[@R12] the adjusted HR of renal and perinephric abscesses was 2.24 (95% CI 1.30 to 3.88),[@R11] the adjusted HR of pyogenic liver abscess was 3.89 (95% CI 3.20 to 4.72)[@R10] and the OR of pulmonary tuberculosis were 1.91 (95% CI 1.06 to 3.44).[@R8]

In this study, after adjusting for potential confounding variables, we also observed that the splenectomy group was at an increased risk of empyema (adjusted HR, 2.89). This phenomenon would typically be regarded as counterintuitive, but the exact reason remains unclear. A possible reason can be that some comorbidities that are potentially associated with empyema should have been included in the study; however, further studies are required to explain this phenomenon. The HR was higher than that observed for comorbidities. HR was not confounded by comorbidities because there was no signiﬁcant difference in the prevalence of comorbidities between the splenectomy and non-splenectomy groups. This indicates that the increased HR of empyema in patients with splenectomy cannot be completely attributed to the prevalence of comorbidities. Although these comorbidities were found to be associated with empyema, to minimise their confounding effects, a further analysis was conducted. It was noted that in absence of any comorbidity, patients with splenectomy continued to have a higher HR of empyema (HR, 4.52). These results indicate that even in the absence of comorbidities, splenectomy may have a unique role in the risk of developing empyema. These ﬁndings are compatible with previously reported findings in the literature, in which patients with splenectomy are more prone to have severe life-threatening infections owing to an immunocompromised condition following splenectomy[@R41] and are at an increased risk of developing empyema.

The limitations of this study as follows. First, some traditional behaviour risk factors, including alcohol consumption and cigarette smoking, were not considered owing to inherent limitations of the insurance database. We used alcohol-related diseases instead of alcohol consumption and chronic obstructive pulmonary disease instead of cigarette smoking. Second, the underlying causes for splenectomy were also not recorded owing to limitation of the database. Splenectomy is common in certain disorders and diseases such as haematological disorders, gastric cancer or trauma; thus, these background conditions may confound the results. We could not clarify the association of the cause of splenectomy with the development of empyema in this study. Third, owing to the limitation of the database, the underlying causes for splenectomy were not recorded. The cause of splenectomy could be the cause of empyema, for example, splenic abscess. Considering the high quality of the Taiwan medical system, 1 month is not required to confirm empyema diagnosis from the onset of empyema prodrome. To reduce biased results, subjects with an empyema diagnosis within 1 month following splenectomy were excluded. Therefore, it is less likely that splenectomy is the cause of empyema. Fourth, empyema could very well correlate with open surgery. However, owing to the previously mentioned limitations, the splenectomy type was not recorded. It is not known if splenectomy was performed via open or laparoscopic surgery or if it was a total or partial splenectomy. Fifth, the lack of vaccination could very well correlate with empyema. However, the number of subjects with splenectomy who were vaccinated against encapsulated bacteria (particularly *Streptococcus pneumoniae*) was unknown; thus, we could not investigate whether pneumococcal vaccination decreased the risk of empyema. Sixth, as causative pathogens were not recorded, the types of bacteria that contributed to empyema development could not be investigated. The lack of such data did not permit us to conclude a substantial causality. This case--control study included only patients with splenectomy, which may limit the generalisability of the study results to the general population. Such a study design does not permit to conclude a substantial causality. Further prospective studies are required to confirm the findings of our study.

To the best of our knowledge, this is the ﬁrst original study to describe the association between splenectomy and empyema. Although the underlying mechanisms that associate splenectomy and empyema could not be completely determined, our ﬁndings are novel and clinically important. In addition, we used a hospitalisation dataset that had a large sample size and substantial statistical power. The diagnosis codes of the included comorbidities have been previously documented.[@R23] The study design and statistical methodology are described in detail, and our results are relatively promising. Because the splenectomy and non-splenectomy groups had similar distributions of the studied comorbidities, the confounding effects of the comorbidities on the risk of empyema appear to be minimal.

The IRR between the splenectomy and non-splenectomy groups reduced from 2.87 in the first 5 years of follow-up to 1.73 in the period following the 5 years. Future studies are required to confirm whether a longer follow-up period would further reduce this average ratio. For the splenectomy group, the overall HR of developing empyema was 2.89 after adjusting for age, sex and comorbidities, which were identified from previous literature (including alcohol-related disease, cancer, chronic kidney disease, chronic liver disease, chronic obstructive pulmonary disease and diabetes mellitus). The risk of empyema following splenectomy remains high despite the absence of these comorbidities.
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